Bod Science (ASX:BOD) - Prezzo delle azioni, notizie e analisi

BOD Panoramica delle azioni

Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. Maggiori dettagli

BOD analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Analisi del rischio

Gli utili sono diminuiti del 4.2% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( A$4M )

Patrimonio netto negativo

Le azioni sono altamente illiquide

+ 2 più rischi

Bod Science Limited Concorrenti

Avecho Biotechnology

ASX:AVE

AU$6.3m

Cann Global

ASX:CGB

AU$5.4m

Epsilon Healthcare

ASX:EPN

AU$7.2m

Argent BioPharma

ASX:RGT

AU$13.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Bod Science
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.024
Massimo di 52 settimane	AU$0.13
Minimo di 52 settimane	AU$0.024
Beta	1.45
1Variazione di 1 mese	0%
Variazione a 3 mesi	-7.69%
Variazione di 1 anno	-65.22%
3Variazione a 3 anni	-94.95%
Variazione a 5 anni	-95.10%
Variazione dall'IPO	-91.72%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	BOD	AU Pharmaceuticals	AU Mercato
7D	0%	-7.0%	1.2%
1Y	-65.2%	34.9%	19.7%

Ritorno vs Industria: BOD ha avuto una performance inferiore rispetto al Australian Pharmaceuticals che ha registrato un rendimento 34.9 % nell'ultimo anno.

Rendimento vs Mercato: BOD ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 19.7 % nell'ultimo anno.

Volatilità dei prezzi

Is BOD's price volatile compared to industry and market?
BOD volatility
BOD Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.8%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Prezzo delle azioni stabile: BOD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di BOD nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2014	n/a	Jo Patterson	bodscience.com

Bod Science Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Bod Science con la sua capitalizzazione di mercato?
BOD statistiche fondamentali
Capitalizzazione di mercato	AU$4.26m
Guadagni(TTM)	-AU$7.95m
Ricavi(TTM)	AU$3.32m

1.3x

Rapporto P/S

-0.5x

Rapporto P/E

BOD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BOD Conto economico (TTM)
Ricavi	AU$3.32m
Costo del fatturato	AU$1.05m
Profitto lordo	AU$2.27m
Altre spese	AU$10.22m
Guadagni	-AU$7.95m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.045
Margine lordo	68.40%
Margine di profitto netto	-239.47%
Rapporto debito/patrimonio netto	-136.9%

Come si è comportato BOD nel lungo periodo?

Vedi performance storica e confronto

BOD Panoramica delle azioni

Analisi del rischio

Bod Science Limited Concorrenti

ASX:AVE

AU$6.3m

ASX:CGB

AU$5.4m

ASX:EPN

AU$7.2m

ASX:RGT

AU$13.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Less than half of directors are independent

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Full year 2022 earnings released: AU$0.051 loss per share (vs AU$0.043 loss in FY 2021)

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Less than half of directors are independent

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

Here's Why We're Watching Bod Australia's (ASX:BDA) Cash Burn Situation

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia (ASX:BDA) Is In A Good Position To Deliver On Growth Plans

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

Why Bod Australia's (ASX:BDA) CEO Pay Matters

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.61

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.53

New 90-day high: AU$0.40

New 90-day high - AU$0.30

Earnings released

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Bod Science Limited Riepilogo dei fondamenti

1.3x

-0.5x

Guadagni e ricavi